NO20073807L - Stabilisering av virussammensetninger - Google Patents

Stabilisering av virussammensetninger

Info

Publication number
NO20073807L
NO20073807L NO20073807A NO20073807A NO20073807L NO 20073807 L NO20073807 L NO 20073807L NO 20073807 A NO20073807 A NO 20073807A NO 20073807 A NO20073807 A NO 20073807A NO 20073807 L NO20073807 L NO 20073807L
Authority
NO
Norway
Prior art keywords
virus
stabilization
virus compositions
compositions
attenuated
Prior art date
Application number
NO20073807A
Other languages
English (en)
Inventor
Gary Jim Calton
Rita Fishelevich
Original Assignee
Aurx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurx Inc filed Critical Aurx Inc
Publication of NO20073807L publication Critical patent/NO20073807L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår stabiliserte virussammensetninger, fortrinnsvis et herpesvirus som kan være en attenuert eller genetisk modifisert herpessimpleksvirus eller varicellazostervirus, og en fremgangsmåte for å stabilisere virus og immuniserende preparater ved tilsetting av sukkeret, fortrinnsvis glukose og aminosyrer, fortrinnsvis lysin.
NO20073807A 2004-12-23 2007-07-20 Stabilisering av virussammensetninger NO20073807L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/021,289 US20060141483A1 (en) 2004-12-23 2004-12-23 Stabilization of viral compositions
PCT/US2005/041062 WO2006071373A1 (en) 2004-12-23 2005-11-14 Stabilization of viral compositions

Publications (1)

Publication Number Publication Date
NO20073807L true NO20073807L (no) 2007-08-15

Family

ID=36612101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073807A NO20073807L (no) 2004-12-23 2007-07-20 Stabilisering av virussammensetninger

Country Status (9)

Country Link
US (2) US20060141483A1 (no)
EP (1) EP1848398A4 (no)
JP (1) JP2008525444A (no)
KR (1) KR20070117542A (no)
AU (1) AU2005322522A1 (no)
CA (1) CA2592323A1 (no)
MX (1) MXPA05008695A (no)
NO (1) NO20073807L (no)
WO (1) WO2006071373A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035455A2 (en) * 2005-09-16 2007-03-29 Merial Limited Stabilizers for freeze-dried vaccines
TW201233803A (en) * 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
CN108588035A (zh) * 2011-06-28 2018-09-28 白血球保健股份有限公司 病毒或细菌的新型稳定方法
LT2741740T (lt) 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
KR102549746B1 (ko) * 2014-12-18 2023-07-03 암젠 인크 안정한 동결된 단순 포진 바이러스 제제
JPWO2021020446A1 (no) * 2019-07-30 2021-02-04

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
DK0487632T3 (da) * 1989-08-15 1998-05-25 Massachusetts Inst Technology Stabiliserede vaccinesammensætninger
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
JPH06234659A (ja) * 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US6013265A (en) * 1996-10-22 2000-01-11 University Of Maryland, Baltimore Vaccine composition for herpes simplex virus and methods of using
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex

Also Published As

Publication number Publication date
AU2005322522A1 (en) 2006-07-06
US20080241187A1 (en) 2008-10-02
EP1848398A1 (en) 2007-10-31
KR20070117542A (ko) 2007-12-12
MXPA05008695A (es) 2008-03-07
EP1848398A4 (en) 2010-02-24
JP2008525444A (ja) 2008-07-17
CA2592323A1 (en) 2006-07-06
US20060141483A1 (en) 2006-06-29
WO2006071373A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
NO20073807L (no) Stabilisering av virussammensetninger
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
MY156422A (en) Methods and compositions for live attenuated viruses
NO20081889L (no) Fast vaksine formulering
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
EP2336174B8 (en) Human monoclonal antibodies against Hendra and Nipah viruses
BR0306925A (pt) Formulações estabilizadas de adenovìrus
WO2007044024A3 (en) Recombinant influenza vectors with tandem transcription units
NO20044941L (no) Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte
WO2006124700A3 (en) P53 vaccines for the treatment of cancers
WO2006110887A3 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
WO2007084435A3 (en) Methods for treating hepatitis c
BE1023213B1 (fr) Complexes issus du cytomegalovirus et leurs utilisations
WO2010068968A8 (en) Methods and compositions for use of a coccidiosis vaccine
EA201390812A1 (ru) Лиофилизированные вирусные составы
EA201000277A1 (ru) Соединения для лечения гепатита с
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2009080715A3 (en) Vaccines for malaria
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
WO2009120339A3 (en) Vectors for delivering disease neutralizing agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application